Ask AI
Beyond A1C in T2D TM 2

CE / CME

Looking Beyond A1C in T2D Care: Incretin-Based Therapy for Cardiometabolic Risk Reduction

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: August 10, 2026

Expiration: August 09, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Jennifer Green, MD, discusses strategies healthcare professionals (HCPs) can take in moving type 2 diabetes (T2D) care beyond A1C alone, with a focus on integrating cardiovascular-kidney-metabolic (CKM) risk assessment and novel incretin-based therapies in individualized care plans. Through guideline-based recommendations and an interactive patient case, learners will explore the latest evidence on GLP-1 and dual GIP/GLP-1 receptor agonists (RAs) and best practices for including these therapies in individualized care plans for patients with T2D and relevant comorbidities being seen in the primary care setting.

The key points discussed in this module are illustrated with thumbnails that can be enlarged by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with diabetes do you provide care for in a typical week?​

For those who practice in academic or community settings, please indicate your practice setting:

A 58-year-old patient with T2D, obesity, hypertension, stage 3a albuminuric chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] 58 mL/min/1.73 m²; urine albumin-to-creatinine ratio [UACR] 85 mg/g), and A1C 7.4% on metformin asks whether an incretin-based therapy is appropriate.

Which factor is MOST important when selecting among available incretin-based therapies for this patient?